Despite the revolutionary arrival of highly effective CFTR modulator therapies (ETI) and the rapid adoption of telehealth, the landscape of cystic fibrosis (CF) care has undergone a permanent, and perhaps concerning, transformation. A recent study published in the Journal of Cystic Fibrosis reveals that patient utilization of essential care services—such as routine pulmonary function tests (PFTs) and in-person outpatient visits—has failed to rebound to 2019 benchmarks, settling into a new, lower-use baseline that has experts questioning the long-term implications for patient surveillance.
The State of CF Care: Key Findings
The descriptive analysis, which evaluated data from 27,719 individuals within the U.S. Cystic Fibrosis Foundation Patient Registry, provides a sobering look at how the post-COVID-19 era has redefined clinical interaction. The study, led by S.E. Atteih and colleagues, followed a cohort of 14,011 adults and 13,708 children, all of whom were diagnosed prior to the start of 2019.
The researchers assessed five core pillars of CF management: outpatient clinic visits, pulmonary function tests (PFTs), respiratory bacterial cultures, multidisciplinary assessments, and the newly introduced variable of telehealth encounters. The results indicate a consistent trend: while care utilization saw a sharp, expected decline in 2020, the subsequent recovery period from 2021 to 2023 failed to bridge the gap to pre-pandemic standards.
Perhaps most striking is the data regarding "comprehensive care"—a composite measure defined as a minimum of four outpatient visits, four PFTs, four bacterial cultures, and one annual multidisciplinary assessment. For adults, the rate of meeting these comprehensive criteria plummeted from 44% in 2019 to just 17% in 2023. While pediatric patients fared slightly better, they too saw a decline, with adherence to the composite measure dropping from 45% to 38% over the same period.
Chronology of a Shifted Care Model
To understand this current plateau, it is necessary to examine the timeline of the last five years, a period defined by overlapping clinical and technological shifts.
2019: The Pre-Pandemic Baseline
In 2019, CF care was anchored in traditional, high-frequency, in-person monitoring. The standard of care prioritized frequent clinic visits to track lung health, collect sputum samples for bacterial surveillance, and conduct spirometry to identify early declines in pulmonary function.
2020: The Pandemic Shock
The COVID-19 pandemic acted as an immediate disruptor. Faced with the extreme vulnerability of the CF population to respiratory infections, clinics across the country suspended elective visits. Utilization metrics hit their absolute nadir in 2020 as the medical community scrambled to adapt to lockdown conditions and the unknown risks of a novel coronavirus.
2021–2023: The ETI Era and Adaptation
As the world emerged from lockdown, the widespread rollout of CFTR modulator therapies—specifically the triple-combination therapy Elexacaftor/Tezacaftor/Ivacaftor (ETI)—fundamentally changed the clinical trajectory of the disease. Many patients reported significant improvements in lung function, weight gain, and overall quality of life. This newfound clinical stability, coupled with a lasting "habituation" to remote care and increased reliance on telehealth, created a new environment where the necessity of frequent in-person hospital visits was openly questioned by both patients and providers.
Supporting Data: Disparities in Utilization
The decline in service utilization is not uniform across all demographics, with adults showing a much steeper departure from 2019 norms than their pediatric counterparts.
The reduction in in-person engagement is best illustrated by the following metrics:
- Outpatient Visits: The proportion of adults attending at least four annual outpatient visits fell from 55% in 2019 to 22% in 2023.
- Bacterial Surveillance: The collection of at least four annual bacterial cultures—essential for identifying emerging pathogens like Pseudomonas aeruginosa or Staphylococcus aureus—dropped from 45% in 2019 to 17% in 2023.
- Telehealth’s Role: While telehealth was positioned as a bridge to maintain contact, it did not act as a total replacement. Data shows that 30% of the total CF population had zero recorded telehealth encounters between 2021 and 2023. This suggests that a significant portion of the patient population has become "unplugged" from the specialized care system, whether by choice or by a lack of clinical necessity as perceived by the patient.
Official Responses and Clinical Perspectives
The medical community is currently divided on how to interpret these findings. On one hand, the reduced frequency of visits is a testament to the success of ETI therapies. When patients feel healthier and are experiencing fewer pulmonary exacerbations, the burden of frequent travel to a CF center becomes a significant lifestyle deterrent.
However, clinical researchers argue that "clinical stability" is not the same as "absence of disease." Cystic fibrosis is a chronic, progressive condition, and the surveillance metrics—specifically PFTs and cultures—were designed to catch silent, asymptomatic declines before they become irreversible.
"Current recommendations now allow for individualized visit frequencies for stable patients aged six and older," notes the study authors. "However, these flexibilities were never intended to replace the fundamental surveillance tools of spirometry and respiratory microbiology." The concern among clinicians is that the current dip in utilization may be driven by a false sense of security. If a patient is no longer attending regular clinics, the "safety net" that catches secondary complications, such as CF-related diabetes or liver disease, is effectively dismantled.
Implications: A New Era of Surveillance
The implications of this shift are profound for both the future of CF care and the broader healthcare system.
1. The Challenge of Individualized Models
Clinicians are now tasked with the difficult balance of respecting patient autonomy and the convenience of modern telehealth while ensuring that surveillance does not lapse. Moving forward, health systems may need to implement more robust home-monitoring programs—such as home spirometry kits that transmit data directly to the medical record—to compensate for the lack of in-person clinic visits.
2. The Risk of Long-term Complications
The primary fear is that the lack of regular surveillance will lead to a delayed diagnosis of complications. By the time a patient presents with symptoms that warrant a visit, the disease process may have already advanced to a stage that is harder to treat. The medical community must determine if the current "low-use" baseline is a safe, sustainable outcome of successful treatment or a dangerous drift away from necessary preventative care.
3. Economic and Structural Shifts
The shift also impacts the economic model of CF care centers. With fewer patients physically entering the clinic, the overhead and funding models for specialized multidisciplinary teams—including respiratory therapists, nutritionists, and social workers—may face instability. If the volume of visits remains low, health systems will need to rethink how these vital team members are integrated into the patient journey, perhaps shifting toward a decentralized model that emphasizes remote coordination.
Conclusion
The data from the Journal of Cystic Fibrosis serves as a wake-up call. While the era of ETI therapy has undeniably improved the lives of thousands, it has also fundamentally altered the relationship between patients and the healthcare system. The industry has reached a crossroads: it must either adapt to this new, less frequent model of care by improving remote diagnostic technologies, or it must reinvigorate the importance of periodic, in-person surveillance. As we move further into the post-ETI era, the priority must be ensuring that "less care" does not become "substandard care."
